130 related articles for article (PubMed ID: 25182961)
41. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
42. Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
Suspitsin EN; Yanus GA; Sokolenko AP; Yatsuk OS; Zaitseva OA; Bessonov AA; Ivantsov AO; Heinstein VA; Klimashevskiy VF; Togo AV; Imyanitov EN
Med Oncol; 2014 Feb; 31(2):828. PubMed ID: 24415413
[TBL] [Abstract][Full Text] [Related]
43. The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers.
Laitman Y; Boker-Keinan L; Berkenstadt M; Liphsitz I; Weissglas-Volkov D; Ries-Levavi L; Sarouk I; Pras E; Friedman E
Cancer Genet; 2016 Mar; 209(3):70-4. PubMed ID: 26778106
[TBL] [Abstract][Full Text] [Related]
44. Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
Fragoso-Ontiveros V; Velázquez-Aragón JA; Nuñez-Martínez PM; de la Luz Mejía-Aguayo M; Vidal-Millán S; Pedroza-Torres A; Sánchez-Contreras Y; Ramírez-Otero MA; Muñiz-Mendoza R; Domínguez-Ortíz J; Wegman-Ostrosky T; Bargalló-Rocha JE; Gallardo-Rincón D; Reynoso-Noveron N; Arriaga-Canon C; Meneses-García A; Herrera-Montalvo LA; Alvarez-Gomez RM
PLoS One; 2019; 14(9):e0222709. PubMed ID: 31545835
[TBL] [Abstract][Full Text] [Related]
45. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.
Gorodetska I; Serga S; Lahuta T; Ostapchenko L; Demydov S; Khranovska N; Skachkova O; Inomistova M; Kolesnik O; Svintsitsky V; Tsip N; Peresunko A; Kmit' N; Manzhura O; Rossokha Z; Popova O; Salomakhina H; Kyriachenko S; Kozeretska I
Fam Cancer; 2017 Oct; 16(4):471-476. PubMed ID: 28285342
[TBL] [Abstract][Full Text] [Related]
47. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.
Tonin PN; Mes-Masson AM; Narod SA; Ghadirian P; Provencher D
Clin Genet; 1999 May; 55(5):318-24. PubMed ID: 10422801
[TBL] [Abstract][Full Text] [Related]
48. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Kringen P; Wang Y; Dumeaux V; Nesland JM; Kristensen G; Borresen-Dale AL; Dorum A
BMC Cancer; 2005 Oct; 5():134. PubMed ID: 16229746
[TBL] [Abstract][Full Text] [Related]
49. Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania.
Janavicius R; Pepalyte I; Kucinskas V
Breast Cancer Res Treat; 2009 Sep; 117(2):467-9. PubMed ID: 18763032
[No Abstract] [Full Text] [Related]
50. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M; Brozek I; Senkus-Konefka E; Jassem J; Stepnowska M; Palomba G; Pisano M; Casula M; Palmieri G; Borg A; Limon J
Oncol Rep; 2008 Jan; 19(1):263-8. PubMed ID: 18097605
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Francis W; Halliday D; Royer R; Zhang S; Li S; Thompson I; Donenberg T; Hurley J; Akbari MR; Narod SA
Clin Genet; 2016 Mar; 89(3):328-31. PubMed ID: 25920394
[TBL] [Abstract][Full Text] [Related]
52. Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study.
Broberg K; Huynh E; Schläwicke Engström K; Björk J; Albin M; Ingvar C; Olsson H; Höglund M
BMC Cancer; 2009 May; 9():140. PubMed ID: 19432957
[TBL] [Abstract][Full Text] [Related]
53. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
Blecharz P; Szatkowski W; Klimek M; Urbański K
Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
[TBL] [Abstract][Full Text] [Related]
54. Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations.
Choi MC; Heo JH; Jang JH; Jung SG; Park H; Joo WD; Lee C; Lee JH; Lee JM; Hwang YY; Kim SJ
Int J Gynecol Cancer; 2015 Oct; 25(8):1386-91. PubMed ID: 26402875
[TBL] [Abstract][Full Text] [Related]
55. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
[TBL] [Abstract][Full Text] [Related]
56. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
[TBL] [Abstract][Full Text] [Related]
57. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
58. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
59. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of BRCA1 founder mutations in western Poland.
Jasinska A; Krzyzosiak WJ
Hum Mutat; 2001; 17(1):75. PubMed ID: 11139251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
